disabling CNS conditions such as depression, anxiety, schizophrenia, cognitive disorders, eating disorders and obesity.

It is increasingly recognized that the use of experimental or translational medicine models can provide a faster route through clinical trials by providing a rapid Go/No-Go signal which conserves resources while allowing more informed decision making during the drug development process.